Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sprint: Lenalidomide in relapsed/refractory MCL
NCT00875667Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2009
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of lenalidomide in mantle cell lymphoma (MCL), sponsored by Celgene Corporation. Started Apr 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00875667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00875667.